Paris, October 7th, 2024,
ProductLife Group (PLG), a global leader in regulatory, scientific, compliance, and digital transformation consulting services for the life sciences industry, today announces the acquisition of IntiQuan AG, a premier Swiss boutique specializing in pharmacometric
services for the biopharmaceutical sector.
Founded in Switzerland in 2015 by Dr. Henning Schmidt, IntiQuan has rapidly established itself as a trusted provider of cutting-edge pharmacometric and statistical modelling & simulation services. The acquisition expands PLG’s portfolio of specialized solutions that support biopharmaceutical companies with drug development, adding a key set of capabilities focused on significantly reducing development risk, costs and timelines and enhancing patient safety through advanced dose-response analyses and predictive safety profiling.
This acquisition represents the next step in PLG’s strategy to create a fully integrated global platform. With further expansions planned across the US and European markets, PLG is well on its way to becoming a leading global provider of comprehensive drug development services.
Xavier Duburcq, CEO of PLG, commented: “We are excited to welcome the IntiQuan team to PLG. They are a very strong fit with our expertise-driven organization. Their deep and highly specialized scientific knowledge in pharmacometrics and clinical pharmacology means that we will enhance the support we provide to our clients in their drug development journey. Pharmacometrics and model-informed drug development offer regulatory grade insights that can impact key decision-making and accelerate clinical development, even eliminating the need for certain trials, in some cases.”
Dr. Henning Schmidt, Founder of IntiQuan, added: “Joining forces with PLG is a pivotal moment for IntiQuan. Our teams support IntiQuan’s clients bringing breakthrough medicines to patients and reducing both time to market and the cost of research and development through our combined solutions. We are excited to contribute our unique capabilities to PLG’s global platform and to play a key role in advancing the future of drug development.”
Dr. Stefan Wetzel, CEO of IntiQuan, said: “There is strong cultural alignment between our organizations centered on providing high-quality, innovative and customer-focused solutions. Together with our PLG colleagues, we look forward to supporting our customers with a broader set of complementary solutions, for example in regulatory services.”
Urs Breitenstein, Partner at Hoffmann & Partner, and Anthony Wimbush, Director at DDA & Company, concluded “We are delighted to have put the force of our international network, AICA, at the disposal of PLG to facilitate this acquisition. Combining our local and sector knowledge and shared results-driven culture, Hoffmann and DDA were able to punch above our weights in the context of a hard-fought sale process, demonstrating the value of cross-border cooperation between advisers as well as their clients.”
